CG Oncology, Inc. (NASDAQ:CGON) Receives $81.73 Consensus Target Price from Analysts

CG Oncology, Inc. (NASDAQ:CGON) has earned an average rating of “Moderate Buy” from the fourteen analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $81.7273.

CGON has been the subject of a number of research analyst reports. Wall Street Zen cut shares of CG Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Truist Financial reissued a “buy” rating and issued a $82.00 price target (up from $77.00) on shares of CG Oncology in a research report on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a research report on Monday, April 20th. Royal Bank Of Canada raised their price target on shares of CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Finally, JPMorgan Chase & Co. raised their price target on shares of CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research report on Monday, May 11th.

Insider Activity at CG Oncology

In other CG Oncology news, Director James Mulay sold 15,600 shares of the firm’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $73.01, for a total value of $1,138,956.00. Following the completion of the transaction, the director owned 15,600 shares of the company’s stock, valued at $1,138,956. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Leonard E. Post sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $54.50, for a total transaction of $54,500.00. Following the completion of the transaction, the director directly owned 1,000 shares of the company’s stock, valued at $54,500. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 18,564 shares of company stock valued at $1,318,170 in the last three months. 4.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CG Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CGON. AQR Capital Management LLC purchased a new position in CG Oncology in the 1st quarter valued at approximately $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of CG Oncology by 18.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company’s stock valued at $876,000 after purchasing an additional 5,442 shares in the last quarter. Millennium Management LLC raised its holdings in shares of CG Oncology by 139.4% in the 1st quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock valued at $14,597,000 after purchasing an additional 347,055 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of CG Oncology by 42.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company’s stock valued at $4,393,000 after purchasing an additional 53,461 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in shares of CG Oncology by 12.3% in the 2nd quarter. Legal & General Group Plc now owns 44,354 shares of the company’s stock valued at $1,153,000 after purchasing an additional 4,847 shares in the last quarter. Hedge funds and other institutional investors own 26.56% of the company’s stock.

CG Oncology Stock Performance

NASDAQ:CGON opened at $59.56 on Monday. The stock has a market capitalization of $5.25 billion, a P/E ratio of -25.56 and a beta of 0.31. The company has a 50 day moving average price of $65.05 and a 200 day moving average price of $56.54. CG Oncology has a fifty-two week low of $23.65 and a fifty-two week high of $75.50.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The company had revenue of $1.08 million for the quarter, compared to analysts’ expectations of $0.45 million. Research analysts forecast that CG Oncology will post -2.89 earnings per share for the current fiscal year.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.